Sidhant Sibal
sidhant
Bharat Biotech and ICMR Announce Interim Results from Phase 3 trials of COVAXIN demonstrates overall Interim Clinical Efficacy of 78% and 100% efficacy against Severe COVID-19 disease: Statement Full statement
Read more